Sienna Biopharmaceuticals, Inc. (SNNAQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sienna Biopharmaceuticals, Inc. (SNNAQ) trades at $0.0001. Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies in immunology and inflammation. The company filed for Chapter 11 bankruptcy in 2019, later converted to Chapter 7. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SNNAQ: SNNAQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNNAQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SNNAQ.
How is this calculated? →Sienna Biopharmaceuticals, Inc. (SNNAQ) Healthcare & Pipeline Overview
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for immunology and inflammation, particularly in dermatology. The company's pipeline includes treatments for psoriasis, atopic dermatitis, and acne, but its operations are currently impacted by Chapter 7 bankruptcy proceedings following an earlier Chapter 11 filing.
What Is the Investment Thesis for SNNAQ?
Investing in Sienna Biopharmaceuticals, Inc. presents significant risks due to its Chapter 7 bankruptcy status initiated in 2019. The company's pipeline, which included SNA-120, SNA-125, and SNA-001, held potential in the dermatology space, targeting conditions like psoriasis, atopic dermatitis, and acne. However, the bankruptcy proceedings have halted clinical trials and development efforts. The company's market capitalization is effectively zero, and the stock trades on the OTC market, indicating high speculation and uncertainty. Any investment decision would hinge on the remote possibility of a restructuring or asset sale that could provide minimal returns to shareholders, but the likelihood is extremely low given the Chapter 7 liquidation.
Based on FMP financials and quantitative analysis
SNNAQ Key Highlights
SNA-120, a TrkA inhibitor, was in Phase IIb clinical trials for psoriasis treatment.
- SNA-125, a topical JAK3 inhibitor, was in Phase I/II clinical trials for atopic dermatitis.
- SNA-001, a topical silver particle suspension, was in pivotal clinical trials for acne and hair reduction.
- The company filed for Chapter 11 bankruptcy on September 16, 2019, later converted to Chapter 7 on December 18, 2019.
- Market capitalization is effectively $0.00B due to bankruptcy.
Who Are SNNAQ's Competitors?
SNNAQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNNAQ's Key Strengths?
Proprietary drug candidates targeting specific pathways in skin.
- Clinical-stage pipeline with potential for addressing unmet needs.
- Experienced management team in dermatology and drug development.
What Are SNNAQ's Weaknesses?
Chapter 7 bankruptcy status.
- Limited financial resources.
- Dependence on successful clinical trial outcomes and regulatory approvals.
What Could Drive SNNAQ Stock Higher?
Potential for asset sale during bankruptcy proceedings.
- Possible restructuring, although highly unlikely.
What Are the Key Risks for SNNAQ?
Financial-distress signal — its Altman Z-Score of -9.50 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-59.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Chapter 7 bankruptcy liquidation.
- Complete loss of investment.
- Limited or no recovery for shareholders.
- Low liquidity and high volatility in the OTC market.
- Lack of financial transparency and regulatory oversight.
What Are the Growth Opportunities for SNNAQ?
- Potential Asset Sale: Although Sienna Biopharmaceuticals is in Chapter 7 bankruptcy, there remains a slim possibility that its assets, including intellectual property related to its drug candidates (SNA-120, SNA-125, and SNA-001), could be sold to another company. This could provide a small return to creditors and potentially shareholders, but the timeline and likelihood are highly uncertain. The value would depend on the perceived potential of these assets by other companies in the dermatology space.
- Restructuring and Revival: In extremely rare cases, companies in Chapter 7 bankruptcy can undergo a restructuring if a viable plan emerges. This would require significant new investment and a complete overhaul of the company's operations. While highly improbable for Sienna given the advanced stage of bankruptcy, it represents a theoretical growth opportunity if new management and funding were secured. The timeline for such a turnaround would be several years.
- Technological Advancements in Dermatology: The dermatology market continues to evolve with advancements in drug delivery systems, personalized medicine, and targeted therapies. If Sienna's intellectual property were to be acquired, these advancements could potentially enhance the value and efficacy of its drug candidates. The timeline for realizing these benefits would depend on the pace of innovation in the dermatology field.
- Partnerships and Collaborations: Even in bankruptcy, there's a remote possibility that Sienna's assets could attract interest from larger pharmaceutical companies seeking to expand their dermatology portfolios. A partnership or collaboration could provide the resources and expertise needed to further develop and commercialize Sienna's drug candidates. The timeline for such a deal is highly uncertain and dependent on external factors.
- Increased Prevalence of Skin Conditions: The increasing prevalence of skin conditions like psoriasis, atopic dermatitis, and acne continues to drive demand for new and effective treatments. This underlying market trend could create opportunities for companies that acquire Sienna's assets and successfully develop and commercialize its drug candidates. The long-term growth potential of the dermatology market remains strong.
What Threats Does SNNAQ Face?
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Unsuccessful clinical trial outcomes.
What Are SNNAQ's Competitive Advantages?
- Proprietary drug candidates (SNA-120, SNA-125, SNA-001).
- Targeted therapies with potential for improved efficacy and safety.
- Intellectual property protection for its drug candidates.
What Does SNNAQ Do?
Sienna Biopharmaceuticals, Inc., founded in 2010 and headquartered in Westlake Village, California, was a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies in the fields of medical dermatology and aesthetics. The company aimed to address unmet needs in areas such as psoriasis, atopic dermatitis, acne, and unwanted hair. Sienna's approach involved developing therapies that selectively target specific pathways in tissues, particularly the skin, to maximize efficacy and minimize systemic side effects. Its lead product candidates included SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A (TrkA), in Phase IIb clinical trials for psoriasis and associated pruritus; SNA-125, a topical dual Janus kinase 3 (JAK3) inhibitor in Phase I/II trials for atopic dermatitis, psoriasis, and pruritus; and SNA-001, a topical suspension of silver particles in pivotal clinical trials for acne and reduction of light-pigmented hair. However, on September 16, 2019, Sienna Biopharmaceuticals filed a voluntary petition for reorganization under Chapter 11 bankruptcy, which was later converted to Chapter 7 on December 18, 2019. This has significantly impacted the company's operations and future prospects.
What Products and Services Does SNNAQ Offer?
- Developed SNA-120, a TrkA inhibitor for psoriasis and pruritus.
- Developed SNA-125, a topical JAK3 inhibitor for atopic dermatitis, psoriasis, and pruritus.
- Developed SNA-001, a topical silver particle suspension for acne and hair reduction.
- Conducted Phase IIb clinical trials for SNA-120.
- Conducted Phase I/II clinical trials for SNA-125.
- Conducted pivotal clinical trials for SNA-001.
- Filed for Chapter 11 bankruptcy, later converted to Chapter 7.
How Does SNNAQ Make Money?
- Focused on developing and commercializing targeted therapies in dermatology.
- Out-licensed or partnered with other companies for commercialization.
- Sought to address unmet needs in psoriasis, atopic dermatitis, acne, and unwanted hair.
What Industry Does SNNAQ Operate In?
Sienna Biopharmaceuticals operated within the competitive biotechnology industry, specifically focusing on dermatology. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical companies and other emerging biotechs. The dermatology market is driven by the increasing prevalence of skin conditions like psoriasis, atopic dermatitis, and acne, creating demand for innovative therapies. However, Sienna's bankruptcy reflects the challenges faced by smaller biotech companies in securing funding and navigating the complexities of clinical development and regulatory approval.
Who Are SNNAQ's Key Customers?
- Patients with psoriasis, atopic dermatitis, and acne.
- Dermatologists and other healthcare professionals.
- Potential pharmaceutical partners for commercialization.
Financial Health
Sienna Biopharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.50 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Sienna Biopharmaceuticals, Inc. stands at -59.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -68.3%, showing how much profit it generates from its asset base. A current ratio of 2.07 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Sienna Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Westlake Village, US. The company is led by CEO David E. I. Pyott. SNNAQ has traded publicly since 2017.
SNNAQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary drug candidates targeting specific pathways in skin.
- Clinical-stage pipeline with potential for addressing unmet needs.
- Experienced management team in dermatology and drug development.
- Ongoing: Potential for asset sale during bankruptcy proceedings.
Bear Case
- Chapter 7 bankruptcy status.
- Limited financial resources.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Ongoing: Chapter 7 bankruptcy liquidation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SNNAQ Latest News
No recent news available for SNNAQ.
SNNAQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNNAQ.
Price Targets
Wall Street price target analysis for SNNAQ.
SNNAQ MoonshotScore
What does this score mean?
The MoonshotScore rates SNNAQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David E. I. Pyott
Managing Director
David E. I. Pyott served as the managing director of Sienna Biopharmaceuticals, overseeing a small team of 13 employees. His background includes experience in the pharmaceutical and healthcare industries. While specific details of his career history and education are not provided, his role involved guiding the company's strategic direction and operations during a challenging period.
Track Record: Due to the company's bankruptcy and limited available information, it is difficult to assess David Pyott's track record at Sienna Biopharmaceuticals. The company's failure to achieve sustainable financial stability and the subsequent Chapter 7 filing overshadow any potential achievements during his tenure. His leadership was ultimately unable to prevent the company's downfall.
SNNAQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sienna Biopharmaceuticals, Inc. does not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may be distressed, bankrupt, or have chosen not to comply with stricter regulations. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often lack transparency and have limited regulatory oversight, increasing investment risk.
- OTC Tier: OTC Other
- Limited or no financial reporting.
- High risk of fraud or manipulation.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting and loss of investment.
- Bankruptcy and potential liquidation.
- Verify the company's current legal status and bankruptcy proceedings.
- Review any available financial statements and disclosures.
- Assess the liquidity and trading volume of the stock.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Research the background and track record of the company's management.
- Determine if there is any potential for asset recovery or restructuring.
- Prior history as a Nasdaq-listed company (before delisting).
- Previous clinical trials and drug development efforts.
- Existing intellectual property related to drug candidates.
Sienna Biopharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does Sienna Biopharmaceuticals, Inc. do?
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing targeted therapies in dermatology. Its pipeline included drug candidates like SNA-120, SNA-125, and SNA-001, aimed at treating conditions such as psoriasis, atopic dermatitis, and acne. However, the company filed for Chapter 11 bankruptcy in 2019, which was subsequently converted to Chapter 7, halting its development efforts and significantly impacting its operations. The company is currently in liquidation.
What do analysts say about SNNAQ stock?
Given Sienna Biopharmaceuticals' Chapter 7 bankruptcy status, there is no current analyst coverage or consensus on the stock. The company's financial difficulties and liquidation proceedings make it a highly speculative investment with a significant risk of complete loss. Any prior analyst ratings or price targets are no longer relevant due to the company's current situation.
What are the main risks for SNNAQ?
The primary risk for SNNAQ is the ongoing Chapter 7 bankruptcy liquidation. This means the company's assets are being sold to pay off creditors, and there is a very low probability of any recovery for shareholders. Additionally, the stock trades on the OTC market, which is characterized by low liquidity, high volatility, and limited regulatory oversight.
What are the key factors to evaluate for SNNAQ?
Evaluate SNNAQ on fundamentals, analyst consensus, and risk factors. Investing in Sienna Biopharmaceuticals, Inc. presents significant risks due to its Chapter 7 bankruptcy status initiated in 2019. Not financial advice.
How frequently does SNNAQ data refresh on this page?
SNNAQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SNNAQ's recent stock price performance?
Sienna Biopharmaceuticals, Inc. (SNNAQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidates targeting specific pathways in skin. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNNAQ overvalued or undervalued right now?
Sienna Biopharmaceuticals, Inc. (SNNAQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SNNAQ before investing?
Before investing in Sienna Biopharmaceuticals, Inc. (SNNAQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available historical data and news reports.
- The company's bankruptcy status significantly impacts its current operations and future prospects.
- Investment in SNNAQ is highly speculative and carries a substantial risk of loss.